Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

The Estrogen Gene Test Co. and General Genetics Corporation Announce the Launch of EstroGeneTM, for Breast Cancer Prevention
  • USA - English


News provided by

Estrogen Gene Test Company

Oct 15, 2013, 03:00 ET

Share this article

Share toX

Share this article

Share toX


Santa Fe, New Mexico (PRWEB) October 15, 2013 -- October 15, 2013, Santa Fe, New Mexico

The Estrogen Gene Test Co. and General Genetics Corporation are pleased to announce the launch of a saliva-based test that can identify polymorphisms in all of the key estrogen metabolism genes.

• EstroGeneTM, a simple saliva-based test that examines the key genes involved in estrogen metabolism, and a powerful, actionable, breast cancer prevention tool for physicians and consumers.

Dr. Veltmann commented, “Since the vast majority of women have no family history of breast cancer,.... (the test) may remove some of mystery behind a breast cancer diagnosis and allow women to take meaningful control of their health."

Post this

Decades of research from top universities and institutions around the world reveal in studies that while mutations on single estrogen metabolism genes do not seem to raise the risk of breast cancer; women who possess two or more mutations are at greater risk have from a 2.7 to 13 fold increased risk of breast cancer than women without mutations.

80% of all breast cancer diagnosis is to women with no family history. EstroGeneTM allows physicians to pinpoint patients at greater risk and clinically intervene to improve estrogen metabolism function. In turn, this may lower their breast cancer risk regardless of their previous or current estrogen exposure, breast cancer status or fertility stage.

EstroGeneTM is recommended for all women and girls, however critical populations to test include women with past, present or future exposure to estrogen-based medications such as hormone replacement therapy, bio-identical hormones and in-vitro fertilization. Women treated for estrogen positive breast cancer, women with a family history of breast cancer and women with severe peri-menopausal symptoms should also test.

Since the first results of the landmark Women’s Health Initiative study published in 2002, which highlighted the two-and-a-half times increased risk of breast cancer to women taking Hormone Replacement Therapy, physicians have struggled with the complexity of relieving menopausal or peri-menopausal symptoms and improving fertility. On the one hand, estrogen based medications may help relieve severe symptoms or promote fertility or allow egg retrieval. On the other hand, breast cancer, as well as other risks, are well known. Physicians no longer need to operate within the 2.5 times increased risk bell curve but can assess each patient’s risk individually and actively work to mitigate that risk by improving estrogen metabolism function.

Dr. Joseph Veltmann, Ph.D., Chief Scientific Officer for the Estrogen Gene Test Company, Founder of the Institute for Individualized Medicine and one of the world’s leading Nutrigenomic experts has been following 350 high risk women with mutation on the genes in the EstroGeneTM for the past 10 years. Out of the 350 women followed, none have developed the breast cancer disease or had a recurrence by following gene specific protocols to improve estrogen metabolism function. Dr. Veltmann commented, “Since the vast majority of women have no family history of breast cancer, the increased availability of this test can allow women to take more meaningful control over their health. It may remove some of the mystery behind a breast cancer diagnosis and its prevention.”

The Estrogen Gene Test Company has partnered with Clinical Testing Laboratory, a division of General Genetics Corporation, as its laboratory partner in the processing of Estrogene™. Clinical Testing Laboratories is CLIA-certified and performs a wide variety of genetic analysis, including pharmacogenomics, genotyping and other sequencing services for partners around the world.

About Estrogen Gene Test Company
The Estrogen Gene Test Co., http://www.estrogengenetest.com, is an outgrowth of the efforts of the Hormonal Cancer Foundation, http://www.hormonalcancer.org, to promote estrogen metabolism genetic testing before, during and after the use of estrogen medications or for women with estrogen receptor positive breast cancer. EGT is strongly committed to genetic testing to prevent breast cancer and is asking all women taking the test to participate in a Hormonal Cancer Foundation longitudinal study examining the outcome of changing gene expression to prevent breast cancer.

For further information, please visit: The Estrogen Gene Test Co, http://www.estrogengenetest.com .

About General Genetics Corporation
General Genetics Corporation is a world-class provider of genetic testing services for the relationship, forensic and clinical testing markets. The Company takes pride in the quality and accuracy of its testing services and has earned accreditation or certification from such organizations as AABB, A2LA, CLIA, ISO17025, NATA, and British Ministry of Justice. The company specializes in relationship testing for paternity, sibling, grand parentage, or other familial and ancestry purposes; forensic testing for establishing identity and profiling suspects for use in civil or criminal cases; and clinical testing for genetic predisposition, pharmacogenomics, disease genotyping, diet and fitness and other emerging clinical applications. The Company markets its testing services in 26 countries on six continents and in eight languages. More information about the genetic testing services available through General Genetics can be found at: http://www.gtldna.com, http://www.ftldna.com, and http://www.ctldna.com.

Contact:
Estrogen Gene Test Co: Stacia Hachem: 1-505-466-5019
General Genetics Corporation: Bud Thompson: 1-540-520-2540

Stacia Hachem, Estrogen Gene Test Company, http://www.estrogengenetest.com, +1 505-466-5019, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.